Helius Medical Technologies - HSDT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.00
  • Forecasted Upside: 2,664.98%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.87
▼ -0.01 (-1.14%)

This chart shows the closing price for HSDT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Helius Medical Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HSDT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HSDT

Analyst Price Target is $24.00
▲ +2,664.98% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Helius Medical Technologies in the last 3 months. The average price target is $24.00, with a high forecast of $24.00 and a low forecast of $24.00. The average price target represents a 2,664.98% upside from the last price of $0.87.

This chart shows the closing price for HSDT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Helius Medical Technologies. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/5/2024Roth MkmBoost TargetBuy ➝ Buy$24.00Low
5/12/2023LADENBURG THALM/SH SHLower Target$100.00 ➝ $85.00Low
12/20/2022Maxim GroupInitiated CoverageBuyLow
8/23/2022Roth CapitalInitiated CoverageBuy$250.00Low
11/15/2021Noble FinancialDowngradeOutperform ➝ Market PerformLow
9/16/2021Noble FinancialReiterated RatingBuy$1,000.00Low
3/24/2021Noble FinancialInitiated CoverageOutperform$1,000.00Medium
2/12/2021LADENBURG THALM/SH SHInitiated CoverageBuyLow
8/12/2020OppenheimerReiterated RatingHoldHigh
5/12/2020OppenheimerInitiated CoverageHoldHigh
8/9/2019BTIG ResearchReiterated RatingHoldN/A
(Data available from 7/19/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/21/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/20/2024
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/20/2024
  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/20/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/19/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Helius Medical Technologies logo
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.
Read More

Today's Range

Now: $0.87
Low: $0.85
High: $0.90

50 Day Range

MA: $1.15
Low: $0.84
High: $1.69

52 Week Range

Now: $0.87
Low: $0.81
High: $13.43

Volume

44,499 shs

Average Volume

95,519 shs

Market Capitalization

$2.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Helius Medical Technologies?

The following sell-side analysts have issued research reports on Helius Medical Technologies in the last twelve months: Roth Mkm.
View the latest analyst ratings for HSDT.

What is the current price target for Helius Medical Technologies?

1 Wall Street analysts have set twelve-month price targets for Helius Medical Technologies in the last year. Their average twelve-month price target is $24.00, suggesting a possible upside of 2,665.0%. Roth Mkm has the highest price target set, predicting HSDT will reach $24.00 in the next twelve months. Roth Mkm has the lowest price target set, forecasting a price of $24.00 for Helius Medical Technologies in the next year.
View the latest price targets for HSDT.

What is the current consensus analyst rating for Helius Medical Technologies?

Helius Medical Technologies currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HSDT will outperform the market and that investors should add to their positions of Helius Medical Technologies.
View the latest ratings for HSDT.

What other companies compete with Helius Medical Technologies?

Other companies that are similar to Helius Medical Technologies include Sonendo, Sintx Technologies, Nuwellis, Bone Biologics and Nyxoah. Learn More about companies similar to Helius Medical Technologies.

How do I contact Helius Medical Technologies' investor relations team?

Helius Medical Technologies' physical mailing address is 642 NEWTOWN YARDLEY ROAD SUITE 100, NEWTOWN PA, 18940. The company's listed phone number is (877) 564-0008 and its investor relations email address is [email protected]. The official website for Helius Medical Technologies is heliusmedical.com. Learn More about contacing Helius Medical Technologies investor relations.